Roche Is ‘Aiming For The Sky’ With Vabysmo Commercial Launch
CEO Severin Schwan compared his enthusiasm for the newly launched eye drug to Ocrevus, the company's top-selling drug.
You may also be interested in...
Roche said it remains deeply committed to the therapeutic area and highlighted a broad clinical pipeline at a virtual investor event.
Lilly's Mounjaro and Roche's Vabysmo appear on track to be fast blockbusters in a year that saw the fewest drug launches since 2016.
The continent's pharmaceutical sector enjoyed another robust quarter with increased productivity, and price increases, softening the blow of rising energy costs and other challenges across the supply chain.